- Drugs
- Thursday, 19 Sep 2019
Aphria Inc Launches Plant Positivity Social Impact Platform with Evergreen
Aphria Inc. announced the launch of its new social impact platform, Plant Positivity. The company partnered with not-for-profit Evergreen which will create six new garden spaces at Evergreen Brick Works.
Aphria, Inc. is engaged in the production and supply of medical cannabis. It operates through three reportable segments including cannabis operations, distribution operations, and business under development. The Cannabis Operations segment produces, distributes, and sells both medical and adult-use cannabis. The Distribution Operations segment are carried out through its wholly owned subsidiaries ABP, FL Group, and CC Pharma. The Distribution under Development segment includes operations in which the firm has not received final licensing or has not commenced commercial sales from operations. The company offers medical cannabis of various strains, including Kusawa, Tamaracouta, Panache, Churchill and Iroquois. The Company is also engaged in the research and development, and commercial production of cannabis oil. The company was founded by Cole Cacciavillani and John Cervini on June 22, 2011 and is headquartered in Leamington, Canada. Aphria’s subsidiaries include Pure Natures Wellness Inc. that are engaged in the production and distribution of medical marijuana, and Cannway Pharmaceuticals Ltd., which specializes in offering support services to veterans and their first responders.
Related Industry Updates
Acute Pancreatitis Market is expected to reach US$ 8,827.37 million by 2030
Sep 08, 2023
North America Radiopharmaceutical Theragnostic Market is expected to reach US$ 1,529.88 million by 2028
Mar 13, 2023
RELIEF THERAPEUTICS and NeuroRx, Inc. File FDA IND for Aviptadil to Treat COVID-19-induced Respiratory Distress
Mar 26, 2020
Brazil Vitamin K2 Market is expected to reach US$ 9.81 million by 2028
Jun 09, 2023
Human Vaccine Adjuvants Market is expected to reach US$ 4,489.23 million by 2030
Jan 04, 2024
Augmenting Cases of Chronic Diseases has increased the usage of Radiopharmaceutical
Sep 06, 2019
Luye Pharma Submits New Drug Application in the U.S. for Its Antidepressant Drug LY03005
Dec 27, 2019